In a groundbreaking move, Cameroon is set to become the first country in Africa to administer a new malaria vaccine.
This initiative, slated to kick off on Monday, marks a significant milestone in the longstanding battle against the mosquito-spread disease that is responsible for 95% of global malaria deaths.
Cameroon, a Central African nation, is leading the charge in the fight against malaria by introducing the Mosquirix vaccine.
With the campaign set to commence this week, officials are optimistic that this effort will bring relief to families and bolster the country’s healthcare infrastructure.
Aurelia Nguyen, Chief Program Officer at the Gavi vaccines alliance, emphasized the life-saving potential of the vaccination, which is expected to play a crucial role in reducing malaria-related fatalities.
“The vaccination will save lives. It will provide major relief to families and the country’s health system,” said Aurelia Nguyen, chief program officer at the Gavi vaccines alliance, which is helping Cameroon secure the shots.
Cameroon’s ambitious plan aims to vaccinate approximately 250,000 children this year and the next, demonstrating a commitment to safeguarding the health of its youngest population.
Gavi, in collaboration with 20 other African countries, is actively involved in facilitating access to the vaccine. The collective goal is to immunize over 6 million children across the continent by 2025, signaling a united front against the pervasive parasitic disease.
The Mosquirix vaccine, produced by GlaxoSmithKline (GSK), has been endorsed by the World Health Organization (WHO) for its potential to significantly reduce severe infections and hospitalizations.
Although the vaccine is approximately 30% effective and requires four doses, it represents a crucial step forward in the fight against malaria. GSK’s production capacity currently stands at around 15 million doses annually.
While Mosquirix shows promise, experts are eyeing a second malaria vaccine developed by Oxford University and WHO-approved in October.
This alternative, more cost-effective vaccine requires three doses, and the Serum Institute of India has committed to producing up to 200 million doses annually.
The potential availability of the Oxford vaccine later this year offers hope for broader immunization efforts.
It’s important to note that neither of the malaria vaccines currently available halts transmission entirely. Complementary measures such as bed nets and insecticidal spraying remain crucial in curbing the spread of the malaria parasite.
As the campaign unfolds in Cameroon, the integration of multiple tools is key to achieving comprehensive protection against this pervasive disease.
Read Also: Iran’s Amir Hossein Firouzpour Wins Gold At 2024 U-23 World Wrestling Championships
Join Our Community: WhatsApp Group 1
Join Our Community: Telegram Channel
